Table 3 Comparison between clinicopathological characteristics of APC according to treatment effect in the training cohort

Age (median, SD)

66 (9.29)

66.5 (9.8)

1.018

0.963–1.076

0.521

Gender

Male

20 (60.6%)

15 (57.7%)

0.886

0.312–2.521

0.821

Female

13 (39.4%)

11 (42.3%)

ECOG PS

0–1

9 (27.3%)

4 (15.4%)

2.062

0.555–7.661

0.280

2

24 (72.7%)

22 (84.6%)

Chemotherapy

Monotherapy

11 (33.3%)

16 (61.5%)

3.200

1.096–9.343

0.033

2.948

0.910–9.553

0.072

Combination therapy

22 (66.7%)

10 (38.5%)

TNM stage

III

5 (15.2%)

5 (19.2%)

0.750

0.192–2.930

0.679

IV

28 (84.8%)

21 (80.8%)

Primary tumor location

Head and neck

15 (45.5%)

16 (61.5%)

0.521

0.183–1.482

0.222

Body and tail

18 (54.5%)

10 (38.5%)

CA19-9 (U/ml)

< 1000

27 (81.8%)

13 (50.0%)

4.500

1.394–14.528

0.012

3.703

1.056–12.988

0.041

≥ 1000

6 (18.2%)

13 (50.0%)

Radiomics signature

< 0.045

24 (72.7%)

11 (42.3%)

3.636

1.220-10.836

0.020

3.382

1.031–11.101

0.044

≥ 0.045

9 (27.3%)

15 (57.7%)